索拉非尼:肾细胞癌靶向治疗的进展

Future Prescriber Pub Date : 2008-07-07 DOI:10.1002/fps.12

Professor Robert E Hawkins, Dr Fiona C Thistlethwaite

{"title":"索拉非尼:肾细胞癌靶向治疗的进展","authors":"Professor Robert E Hawkins, Dr Fiona C Thistlethwaite","doi":"10.1002/fps.12","DOIUrl":null,"url":null,"abstract":"<p>Sorafenib is the first dual action oral multi-kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 2","pages":"11-13"},"PeriodicalIF":0.0000,"publicationDate":"2008-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.12","citationCount":"0","resultStr":"{\"title\":\"Sorafenib: advances in targeted therapy for renal cell carcinoma\",\"authors\":\"Professor Robert E Hawkins, Dr Fiona C Thistlethwaite\",\"doi\":\"10.1002/fps.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Sorafenib is the first dual action oral multi-kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"7 2\",\"pages\":\"11-13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.12\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Sorafenib: advances in targeted therapy for renal cell carcinoma

Sorafenib is the first dual action oral multi-kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量